Mirabegron, the first b3-adrenoceptor agonist introduced for use in clinical practice, differs from antimuscarinic agents in terms of mechanism of action. This review discusses various perspectives on mirabegron in terms of efficacy, mechanism of action, pharmacokinetics, safety, and tolerability for overactive bladder syndrome in studies conducted thus far. Mirabegron administered at daily doses of 25 mg, 50 mg, and 100 mg demonstrated significant improvements in micturition frequency, urgency incontinence, and mean volume voided/micturition as early as the first assessment, and these were maintained throughout the treatment course. Mirabegron seemed well tolerated. The most common adverse events observed with mirabegron in clinical trials were hypertension, nasopharyngitis, and urinary tract infection. The incidence of dry mouth was similar to that with placebo, between 3-and 5-fold lower than with 4 mg tolterodine extended release. Considering that dry mouth is the most bothersome adverse event associated with antimuscarinic drugs and often a reason for treatment discontinuation, mirabegron may be a valuable treatment option for these patients. The benefit of mirabegron (at doses of 50 mg and 100 mg) was also evident in elderly patients and in both treatment-naive patients and those who previously discontinued antimuscarinic therapy. Mirabegron can also be used in combination with antimuscarinics or in addition to alpha blockers. Mirabegron may quickly become a standard treatment of overactive bladder syndrome.
Introduction
Overactive bladder (OAB) syndrome is a highly prevalent condition characterized by the presence of urinary urgency, with or without urgency urinary incontinence, usually with frequency and nocturia. 1 Epidemiological data suggest that OAB syndrome is present in about 12% of all adult men and women, although prevalence rates increase with aging in both sexes. 2 In Asia, the prevalence among adult men in India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, Korea, Taiwan, China, Hong Kong, and Thailand has been estimated as 29.9%. 3 Antimuscarinics are the standard first-line drug therapy for OAB syndrome. 4, 5 They have been suggested to reduce detrusor activity and improve bladder capacity via additional mechanisms, including direct inhibition of bladder afferent signaling at the level of the urothelium and suburothelium. 6 However, some patients have a suboptimal response to antimuscarinics or may experience adverse effects such as dry mouth or constipation. 7, 8 Therefore, a high proportion of patients discontinue antimuscarinic therapy, with fewer than 25% remaining on treatment at 1 year. 9 A b3 adrenoceptor agonist acts on a different molecular pathway. b3-Adrenoceptors are the predominant b-receptor subtype in the urinary bladder 10 and are known to promote urine storage in the bladder by inducing detrusor relaxation in animal and human bladders. 11e13 Mirabegron is the first b3-adrenoceptor agonist 14 to have been approved for the treatment of OAB syndrome (in Japan, the United States, Europe, Canada, Australia, Hong Kong, Korea, and Taiwan). Product labeling differs between countries, with a recommended starting dose of 25 mg once daily (QD) in the United States and Canada (Myrbetriq, Astellas Pharma Inc., Northbrook, IL, USA), with an option to increase to 50 mg, and a recommended dose of 50 mg QD in Japan (Betanis, Astellas Pharma Inc., Chuo-ku, Tokyo, Japan) and Europe (Betmiga, Astellas Pharma BV, Leiden, The Netherlands), with the 25-mg dose reserved for special populations (e.g., those with severe renal impairment or moderate hepatic impairment). 15 In Taiwan, the recommended starting dose was 25 mg QD, with an option to increase to 50 mg. Mirabegron has been studied extensively over approximately 10 years, and > 5500 patients with OAB syndrome have received mirabegron in Phase II and III studies. 15 Most of the studies shared similar designs, although the doses of mirabegron and inclusion of placebo and/or an active control arm with 4-mg tolterodine extended release (ER) varied across trials ( 
Mechanism of action
Detrusor relaxation is primarily mediated by the cyclic adenosine monophosphate pathway, activated via the binding of norepinephrine to b-adrenoceptors. Three subtypes of b-adrenoceptors (b1, b2, and b3) have been identified in the detrusor muscle and urothelium. 24, 25 b3-Adrenoceptors account for > 95% of all b-adrenoceptors mRNA in the human bladder and are thought to be the main b-adrenoceptors mediating human detrusor relaxation. 10, 11 Stimulation of b3-adrenoceptors elicits direct relaxation of detrusor smooth muscle; the underlying cellular mechanisms are not fully clear but may involve activation of adenylyl cyclase and subsequent increases in the intracellular levels of cyclic adenosine phosphate and Ca channels. 26 Mirabegron shows high intrinsic activity for b3-adrenoceptors and very low intrinsic activity for b1 and b2 adrenoceptors. In Chinese hamster ovary cells that express human b3-adrenoceptors, the half-maximal effective concentration (EC 50 ) value was 22.4nM compared with EC 50 values > 10,000nM
for b1 and b2 adrenoceptors.
14 Mirabegron improves the storage capacity of the bladder without impairing bladder contraction during voiding.
Pharmacokinetics
Mirabegron is rapidly absorbed after oral administration and circulates in plasma in its unchanged form, its glucuronic acid conjugates, and other metabolites, which are pharmacologically inactive. Mirabegron is metabolized in the liver via multiple pathways and is recovered in urine (55%) and feces (34%) mainly in its unchanged form. 27 Because mirabegron is metabolized by cytochrome P450 (CYP) 3A4 28 and, to a minor extent, by CYP2D6 in humans, 29 it may be subject to clinically relevant drugedrug Table 1 Overview of studies. a BLOSSOM [16] DRAGON [17] SCORPIO [18] ARIES [19] CAPRICORN [20] TAURUS [21] Japan's Study [22] Asian's Study [23] Patients randomized interactions and should therefore be used with caution in patients who are taking ketoconozole or other potent CYP3A inhibitors.
Clinical efficacy
In the proof-of-concept BLOSSOM study, 16 mirabegron (100 mg and 150 mg, BID) showed statistically significant improvement versus placebo in the mean change of micturition frequency from baseline to the final visit (p < 0.01). The mean volume voided (MVV)/micturition was dose-dependently increased in the mirabegron groups, with a significant difference between the placebo group and 150-mg mirabegron group (p < 0.05). Urgency episodes in 24 hours decreased significantly for both mirabegron groups (p < 0.05). Statistically significant improvements in changes in incontinence episodes, urgency incontinence [urge urinary incontinence (UUI)] episodes, and nocturia episodes were also observed for 100 mg mirabegron (p < 0.05). In the dose-ranging DRAGON study, the primary efficacy results showed dose-dependent decreases in mean number of micturitions in 24 hours, which were statistically significantly different between the placebo and 50-, 100-, and 200-mg mirabegron groups (p < 0.05, Table 2 ). In addition, from baseline to final follow-up visit, the mean improvements in MVV, incontinence episodes, UUI episodes, urgency episodes, level of urgency, and nocturia episodes were statistically significant. 17 For SCORPIO, ARIES, and CAPRICORN studies, statistically significant improvements were found for both doses of mirabegron compared with placebo in both the coprimary end points (p < 0.05; Table 2 ). In the SCORPIO study, statistically significant improvements in MVV and mean number of UUI episodes in 24 hours were found from baseline to final follow-up visit (p < 0.05). 18 These secondary efficacy results were confirmed by ARIES, which showed statistically significant improvements in MVV, level of urgency number of UUI episodes, urgency episodes, and nocturia episodes in 24 hours from baseline to final visit, and in number of incontinence episodes and micturitions in 24 hours from baseline to Week 4 for both mirabegron groups compared with the placebo group (all p < 0.05). 19 With regard to observations at earlier time points in the CAPRICORN study, 20 
Asian's study [23] Micturition 30 reported primary and secondary efficacy data from a prespecified pooled analysis of these three studies. In the pooled efficacy analysis, 2542 patients were included. Additional secondary end points included two responder analyses based on incontinence episodes at the final visit [patients who were incontinent at baseline who recorded zero incontinence episodes at the final visit (dry rate) and patients with a 50% decrease from baseline in mean number of incontinence episodes in 24 hours] and a post hoc analysis of the proportion of patients with < 8 micturitions in 24 hours at the final follow-up visit. In all cases, the percentages of patients were significantly higher in the 50-and 100-mg mirabegron groups than in the placebo group (p < 0.05). Although the TAURUS study was not designed to demonstrate a statistically significant difference in efficacy between the treatment groups, the 50-and 100-mg mirabegron groups showed numerical improvements from Month 1 to Month 12 in mean number of micturitions in 24 hours, incontinence episodes in 24 hours, and MVV/micturition. 21 At the final visit, the percentage of responders for zero incontinence episodes was 43.4% and 45.8% in the 50-and 100-mg mirabegron groups, respectively. The percentages of responders with 50% decrease from baseline in mean number of incontinence episodes in 24 hours was 63.7% and 66.3%, respectively. In addition, the efficacy profile of 50 mg mirabegron also appears to be maintained over 12 months. 31 In a study in Japan, 22 In a systematic literature review and mixed treatment comparison between 50 mg mirabegron and antimuscarinics in patients with OAB syndrome, the Bayesian mixed treatment comparisons showed that 50 mg mirabegron was as efficacious as antimuscarinics in reducing the frequency of micturition incontinence and UUI episodes, with the exception of 10 mg solifenacin, which was more efficacious than 50 mg mirabegron in improving micturition frequency and UUI frequency. 32 In another study that evaluated the effects of treatment for OAB on health-related quality of life (HR-QoL), mirabegron showed quicker and superior improvement in HR-QoL than 4 mg tolterodine ER. 33 5. Safety and tolerability
General safety and tolerability
In general, treatment with mirabegron was well tolerated. In the BLOSSOM study, treatment-emergent adverse events (TEAEs) were reported, with an incidence of 18.5% and 24.6% in the 100-and 150-mg mirabegron BID groups, respectively, compared with 24.2% in the placebo group and 26.6% in the 4-mg tolterodine ER group. 16 The rates of discontinuation owing to adverse events (AEs) were low at 4.6% (100 mg mirabegron, BID), 7.7% (150 mg mirabegron, BID), 1.5% (placebo), and 3.1% (4 mg tolterodine ER, QD). In the DRAGON study, the incidence of TEAEs was comparable between the mirabegron and placebo groups (20.1%, 22.5%, 21.4%, and 22.2% in the 25-, 50-, 100-, and 200-mg mirabegron groups, respectively, vs. 15.4% in the placebo group). 17 Discontinuation rate due to AEs was low at 2.4e5.3% in the mirabegron groups, 3.0% in the placebo group, and 1.2% in the tolterodine ER group. Pooled safety data from the SCORPIO, ARIES, and CAPRICORN studies showed that the overall incidence of TEAEs was similar across treatment groups and that no evidence of a doseeresponse relationship was found across the mirabegron treatment groups for overall incidence rates of TEAEs (Table 3) . 30, 34, 35 The most common drug-related TEAEs in the mirabegron groups were hypertension and headache, which occurred at a similar incidence rate in the placebo and tolterodine groups, and dry mouth, which occurred at a similar incidence rate in the mirabegron and placebo groups but occurred 5-fold more frequently in the tolterodine group (2.0% in the total mirabegron groups vs. 2.1% in the placebo group and 10.1% in the tolterodine group). In the 12-month TAURUS study, the incidence of TEAEs was similar across the 50-mg mirabegron (59.7%), 100-mg mirabegron (61.3%), and 4-mg tolterodine ER groups (62.6%). 21 The most frequent TEAEs included hypertension, dry mouth, constipation, and headache, occurring at similar incidence rates across the treatment groups, except for dry mouth, which was highest in the tolterodine group (8.6%; 50-and 100-mg mirabegron groups, 2.8% and 2.3%, respectively). Discontinuation owing to AEs was comparable across the treatment groups, occurring in only 6.4%, 5.9%, and 6.0% of the patients who were receiving 50-, 100-, and 4-mg tolterodine ER, respectively. Table 3 Adverse events (AEs) associated with antimuscarinics: incidence with mirabegron, placebo, and 4 mg tolterodine extended release (ER) in a pooled analysis of data from the SCORPIO, ARIES, and CAPRICORN studies [15] . None of the patients in the BLOSSOM study 16 reported serious AEs (SAEs), and SAEs were reported in < 2% of patients across treatment groups in the DRAGON study. 17 In the 12-month TAURUS study, the incidence of treatment-emergent SAEs was similar between the 50-mg mirabegron (5.2%), 100-mg mirabegron (6.2%), and 4-mg tolterodine ER groups (5.4%). Most SAEs were considered unrelated to the study drug. 21 The incidence of AEs in the mirabegron group was similar to that in the placebo group, and most AEs were mild in both the Japanese 22 and Asian studies. 23 In a systematic literature review and mixed treatment comparison between 50-mg mirabegron and antimuscarinics in patients with OAB syndrome, 50-mg mirabegron showed an incidence of dry mouth similar to that with placebo and significantly lower than that with all the included antimuscarinics. 32 Although antimuscarinics may increase ocular pressure, which makes them unsuitable for treatment of patients with uncontrolled narrow angle glaucoma, oral intake of 100-mg mirabegron (QD) for 8 weeks did not increase intraocular pressure in healthy volunteers and was generally safe and well tolerated. 36 
Cardiovascular safety
A randomized, placebo, and active-controlled (400 mg moxifloxacin), parallel, crossover heart rate-corrected QT interval (QT/ QTc) study in 352 healthy individuals found that mirabegron at a dose of 50-or 100-mg did not cause QTc prolongation. 37 Only at a supratherapeutic dose (200 mg) was the QTc interval prolonged in women. However, these findings were not replicated in other large clinical studies. Electrocardiogram findings revealed no overt trends in central tendency or categorical outliers for QTc interval assessment across treatment groups. 15 Data from healthy volunteers showed a mirabegron-related doseeresponse elevation in heart rates of 6.7 bpm, 11 bpm, and 17 bpm for the 50-, 100-, and 200-mg dose groups, respectively, and 24-hour mean increases in systolic blood pressure of 3.0 mmHg, 5.5 mmHg, and 9.7 mmHg, respectively, compared with the placebo group. 37 However, in the pooled Phase III clinical studies with a large number of patients, the change in mean pulse rate for mirabegron was approximately 1 bpm compared with placebo, similar to the change from baseline pulse rate described for antimuscarinics. 15 In the pooled population from the SCORPIO, ARIES, and CAPRICORN, 30 and 12-month TAURUS study, 21 mirabegron was associated with an increase of 1 mmHg in blood pressure compared with placebo. The incidence of hypertension was also similar between the total mirabegron, placebo, and 4-mg tolterodine ER groups. 15 Although the observed cardiovascular effects were minimal and not clinically relevant as far as we know from the large number of patients included in randomized clinical trials, even such minimal modifications in heart rate and blood pressure could have some impact in individuals with significant cardiovascular risk factors or concomitant cardiovascular disease, as often found in elderly patients with OAB syndrome. Postmarketing pharmacovigilance will be of extraordinary importance because we are evaluating a totally new class of drug. 38 
Urinary retention
No clinically relevant effects on postvoid residual (PVR) volume were reported in the BLOSSOM study. 16 When the safety set for the pooled population from the SCORPIO, ARIES, and CAPRICORN studies were analyzed (n ¼ 4611 patients), the mean change from baseline to final visit in PVR volume was unremarkable across treatment groups. 30 No episodes of acute urinary retention were reported in the DRAGON study. 17 In the pooled population, the incidence of urinary retention was low and even lower in mirabegron-treated patients than in placebo or tolterodine-treated patients [total mirabegron, n ¼ 1 (< 0.1%); placebo, n ¼ 7 (0.5%); and tolterodine, n ¼ 3 (0.6%)]. 30 In the 12-month TAURUS study, one patient each in the 50-and 100-mg mirabegron groups and three patients in the 4-mg tolterodine ER group reported urinary retention (confounded by a prior lumbar stenosis procedure in the 100-mg mirabegron group). Acute urinary retention requiring catheterization was reported by none, one, and one patient in the 50-, 100-, and 4-mg tolterodine ER groups, respectively.
21
In another urodynamic study of mirabegron in males with lower urinary tract symptoms (LUTS) and bladder outlet obstruction, 12 weeks of treatment with 50-and 100-mg mirabegron did not adversely affect voiding urodynamics (Q max and PdetQ max ) compared with placebo in male patients with LUTS and significant bladder outlet obstruction. 39 
Perspectives
Although the therapeutic effect of mirabegron was statistically significant compared with placebo, the observed benefit on efficacy end points was not remarkable. It can be assumed that in most of the patients, symptoms will be only partially improved, as with antimuscarinics. Despite that, mirabegron may represent a revolution in the treatment of patients with OAB syndrome, and it is supposed to quickly become a standard treatment of OAB syndrome because of its favorable AE profile. However, the available data cannot allow us to identify the most appropriate role for the drug as either first-or second-line therapy after antimuscarinics, and randomized clinical trials that aim to identify the best sequences of treatments are warranted, 38 as well as cost-effectiveness analyses. 40 The availability for the first time of a second class of oral drug may open the door to the combination of mirabegron and an anticholinergic, which, considering the different mechanisms of action, might be effective. Abrams et al 41 conducted a randomized, doubleblind, dose-ranging, Phase II study to evaluate the efficacy and safety results of combination treatment with mirabegron and solifenacin in patients with OAB syndrome (Symphony). 41 In one of the 12 groups, 1306 patients (66.4% female) were randomized to 12 weeks of treatment as follows: six combination groups (2.5-, 5-, or 10-mg solifenacin plus 25-or 50-mg mirabegron), five monotherapy groups (2.5-, 5-, or 10-mg solifenacin, or 25-or 50-mg mirabegron), or placebo. All the combinations with 5-or 10-mg solifenacin significantly improved the MVV/micturition, with adjusted differences ranging from 18.0 mL to 26.3 mL, compared with 5 mg solifenacin monotherapy. Compared with 5 mg solifenacin, three combination groups significantly reduced micturition frequency, ranging from À0.80 to À0.98. Five of six combinations significantly reduced urgency episodes, ranging from À0.98 to À1.37, compared with 5 mg solifenacin. No dose-related trends in TEAEs, blood pressure, pulse rate, PVR volume, or laboratory or electrocardiogram parameters were observed between the combination and monotherapy groups, although the incidence of constipation was slightly increased with the combination therapy. They concluded that combination therapy with solifenacin/mirabegron significantly improved MVV, micturition frequency, and urgency compared with 5 mg solifenacin monotherapy. All the combinations were well tolerated, with no important additional safety findings compared with the monotherapy or placebo. In addition, considering the high prevalence of storage symptoms in men with voiding LUTS that are suggestive of benign prostatic obstruction (BPO), mirabegron might also be a valuable option in combination or sequential treatments with alphablockers, considering the lack of effects on PVR volume. Ichihara et al 42 44 One hundred twenty-four patients (72% male) were assigned to either a control or an 8-week mirabegron treatment group. Mirabegron significantly decreased the total OAB symptom score, daytime and nighttime micturition frequencies, urinary urgency, urgency incontinence score, and International Prostrate Symptom Score-QoL index in patients with newly diagnosed OAB syndrome. In addition, PVR urine volume did not significantly change throughout the study period. No significant difference was found between response and PVR volume in men and women. The authors concluded that mirabegron is safe and effective for OAB syndrome refractory to antimuscarinics. In another post hoc subgroup analysis, mirabegron provided treatment benefits both in patients with OAB syndrome who were antimuscarinic treatmentnaive and in patients who had received prior antimuscarinic treatment. 45 Further analyses were performed to identify suitable candidates for mirabegron therapy. A post hoc analysis of pooled data from three randomized Phase III trials showed that the treatment effect for incontinence and urgency episodes increased with increasing severity of incontinence at baseline. 46 Another prospective subanalyses of individual and pooled efficacy and tolerability data from three 12-week, randomized, Phase III trials, and of tolerability data from a 1-year safety trial were conducted in order to evaluate the efficacy and tolerability of mirabegron in subgroups of patients aged ! 65 years and ! 75 years. 47 In both age groups, hypertension and urinary tract infection were among the most common TEAEs. The incidence of dry mouth, a typical anticholinergic TEAE, was up to 6-fold higher among the older patients randomized to receive tolterodine than among those randomized to receive any dose of mirabegron. These analyses have demonstrated the efficacy of mirabegron over 12 weeks and the tolerability of mirabegron over 12 weeks and 1 year in patients with OAB syndrome aged ! 65 years and ! 75 years, supporting mirabegron as a therapeutic option for older patients with OAB syndrome.
Patients with neurogenic LUTS may also benefit from mirabegron therapy; however, such trials are awaited. Trials on head-tohead comparisons with solifenacin are also awaited. In addition, other selective b3-adrenoceptor agonists are currently in development. Results of Phase II trials have been reported for solabegron in incontinent female patients with OAB syndrome, 48 and preclinical studies have been reported for ritobegron 49, 50 and TRK-380. 51 
Conclusion
Mirabegron is the first in a new class of agents and is the first new class of oral pharmacological therapy for OAB syndrome for more than 30 years. Although the inclusion and exclusion criteria in these trials limit the ability to extrapolate the results beyond the populations studied, the outcomes of the use of this therapy both alone and in combination with other pharmacotherapeutic agents in real-life clinical practice are awaited with interest.
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